Tacrine-allyl/propargylcysteine-benzothiazole trihybrids as potential anti-Alzheimer's drug candidates by Hiremathad, Asha et al.
1 
Tacrine-allyl/propargylcysteine-benzothiazole trihybrids as potential  
anti-Alzheimer´s drug candidates 
Asha Hiremathad,a,b Karam Chand,a A. Raquel Esteves,c Sandra M. Cardoso,c,d 
Rona R. Ramsay,e Sílvia Chavesa, Rangappa S. Keri,b,* M. Amélia Santosa,* 
a Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, 
Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal. 
b Centre for Nano and Material Sciences, Jain University, Jain Global Campus, 
Bangalore, Karnataka, 562112, India. 
c CNBC – Centro de Neurociências e Biologia Celular, Universidade de Coimbra, 
Coimbra, Portugal. 
d Faculdade de Medicina, Universidade de Coimbra, 3030 Coimbra, Portugal. 
e Biomedical Sciences Research Complex, University of St Andrews, Biomolecular 
Sciences Building, North Haugh, St Andrews KY16 9ST, UK. 
Keywords: Alzheimer´s disease; Trihybrid drugs; Tacrine; Anti-Aβ aggregation; 
MAO-B; Anti-neurodegeneration 
* 
Corresponding Authors: 
*For M.A.S.: phone, +351-218419273; email, masantos@ist.utl.pt 
*For K.S.R.: phone, +91-8027577199; email, keriphd@gmail.com 
2 
Abstract 
On continuing our research on new drug candidates for Alzheimer´s disease (AD), we 
have designed, synthesized and evaluated a series of multifunctional trihybrid agents. 
The design strategy was based on the incorporation of a benzothiazole (BTA) moiety on 
a series of very recently reported bihybrids, resulting from the conjugation of a tacrine 
(TAC) with natural based moieties, namely S-allylcysteine (SAC) (garlic constituent) 
and S-propargylcysteine (SPRC). Thus, in addition to the acetylcholinesterase inhibition 
(AChEI) and anti-ROS capacity of the bihybrids (TAC-SAC/SPRC), the new trihybrids 
(TAC-SAC/SPRC-BTA) appeared endowed with 5-fold capacity for inhibition of the 
amyloid beta-peptide (Af3) aggregation. The BTA moiety led also to considerable 
enhancement of the AChEI on the trihybrids, which molecular modeling suggested as 
being due to the simultaneous binding to the catalytic active site and peripheral anionic 
site of AChE. The trihybrids were also assessed for the MAO inhibition, but resulted in 
lower activity than expected, ascribed to the low accessibility of the propargyl groups to 
the enzyme active site. Finally, the effects of the compounds on the viability of 
neuroblastome cells stressed with Af342
 and
 H2O2 showed moderate cell protection. Overall, 
the performed studies illustrate the importance (and limitations) of enclosing several 
molecular scaffolds in one molecular entity to allow the modulation of multiple AD 
targets. 
1. Introduction 
Alzheimer´s disease (AD) is one of the most devastating age-related neurodegenerative 
disorders with no cure so far, characterized by progressive memory loss and other 
cognitive impairements. The increase of life expectancy of humans and the exponential 
rise in the number of cases of AD support the need for developing an effective treatment 
for this frontline health problem.1 Although its etiology has not been yet well understood, 
the patient brains are characterized by f3-amyloid (Af3) deposits (plaques) around neurons 
and neurofibrillary tangles (NFT) inside neurons,2 increased oxidative stress and disruption 
of metal homeostasis.3 Other prominent features of AD are disturbances in 
neurotransmitters, especially acetylcholine (cholinergic) deficit due to its hydrolysis by 
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acetylcholinesterase (AChE). Since around two decades ago, AD patients have been 
mainly treated with inhibitors of AChE (AChEI), but with limited therapeutic success. In 
fact they can provide amelioration of symptoms (improving patient memory) for a limited 
time window and for mild situations, but cannot alter the course of the disease.4 The 
multifactorial nature and the complexity of AD is believed to be the main reason for the 
absence of effective drugs, and has lead to the emergence of multitargeting drugs. Under 
this approach, one molecular entity is conveniently polyfunctionalized to enable its 
simultaneous binding interaction with several of the most important targets, but mostly 
focused on inhibition of AChE and Aβ-aggregation and/or on the control of the brain 
oxidative stress.5 Monoamine oxidase (MAO) has also been considered an important 
target for the treatment of AD,6 since it catalyzes the oxidative deamination of the 
monoamine based neurotransmitters, such as serotonine and dopamine, with the 
concomitant production of H2O2 that can promote the Fenton reaction and formation of 
reactive oxygen species (ROS).7 
In this context, the development of multitargeting drugs for treatment of AD has been a 
challenge for many research groups.8,9,10 Most of the multitarget drug design strategies 
have been driven by the recognized importance of maintaining the cholinergic functions 
(cholinergic hypothesis). Thus, they include a main molecular framework based on 
approved anti-AD drugs (AChE inhibitors), which is modified (hybridized) with other 
functional units to hit other disease targets. Among the USA FDA anti-AD drugs that are 
AChEI (e.g. tacrine, donepezil, rivastigmine, and galanthamine),11 tacrine was the first 
and most potent AChEI (discontinued due to side effects such as hepatotoxicity),12 with 
superiority in the structural modification, thus making it a priviliged structure for 
incorporation into the overall molecular skeletons of the multi-target-directed drugs for 
the treatment of AD.13 In fact, we can find tacrine hybrids containing fragments of 
donepezil or galanthamine, while also a number of hybrids containing a structural 
fragment derived from natural based products such as alkaloids, flavonoids or others. 
An important part of our current research has also been a focus on the development of 
acetylcholine esterase inhibitors functionalized for the inhibition/modulation of other AD 
targets, namely Aβ aggregation, oxidative stress and redox-active metal ions.14,15,16 Very 
recently, the conjugation of tacrine (TAC) with S-allylcysteine (SAC) and S- 
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propargylcysteine (SPRC), two natural based products with neuroprotective and 
antioxidant roles (e.g. garlic derivatives),17,18 resulted in a set of bihybrids (TAC-SAC and 
TAC-SPRC) with important neuroprotecting properties which, besides the expected 
AChEI and anti-oxidant properties, presented also inhibitory activity for the self- and Cu-
induced Af3 aggregation.19,20 Interestingly, N-propargylamine is also an important 
pharmacophore used in the design of MAO inhibitors.8,21 In this work we report the 
design, synthesis and biological evaluation of a new set of trihybrids (see Fig. 1) which, 
Insert here Fig 1 
in addition to the functional groups presented in the above bihybids, include also a 
benzothiazole (BTA) moiety to enhance the inhibition of Af3 aggregation, since BTA is a 
derivative of thioflavine T (ThT), a well known Af3 dye widely used in the design of AD 
drugs.14,22 Furthermore this new set of eight hybrids was designed by selection of suitable 
linkers to enable a dual mode binding, via the tacrine and BTA moieties, with both active 
binding sites of AChE. Besides the description of the design and synthetic procedures, we 
include herein the results and discussion of the bioassays, namely the inhibition of AChE, 
Af3 aggregation, MAOs and anti-oxidant properties, as well as their effect on the neuronal 
cell viability upon being subjected to model stressors of AD. 
2. Results and Discussions 
2.1 Molecular design and modeling 
The design of the new trihybrids, to be subsequently prepared and studied (Fig. 2), 
involved a preliminary selection of the three molecular scaffolds, to address for main 
biological symptoms associated with AD, and then docking simulations were carried out 
to set the optimal length of the linker between the main frameworks. 
Insert here Fig 2 
The selection of the main molecular moieties was based on our previous works, 
specifically: tacrine (TAC) and the natural based S-allylcysteine (SAC) or S-
propargylcysteine (SPRC) to endow the hybrids with anti-AChE and anti-oxidant 
properties;19 benzothiazole (BTA) to promote the interaction with Af3 and anti-Af3 
aggregation properties; on the other hand, an adequate linkage of TAC with BTA to 
warrant a dual binding mode within the active site of AChE and increase the enzymatic 
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inhibition.14 Based on previous studies, an alkyl-amide linker could avoid linker strain 
and the length was selected based on docking simulation of the ligand into the enzyme, 
TcAChE. These studies also explained the interaction modes of the trihybrids with AChE. 
Preliminairy docking results showed that three to five methylenes could provide the linker 
with adequate length to enable the dual mode interaction with the two molecular 
fragments (TAC, BTA) within the AChE gorge. A more detailed analysis of the 
simulation results shows that the trihybrids could simultaneously bind to both the catalytic 
anionic site (CAS) and the peripherical anionic site (PAS) (see representative results of 
the docking studies in Fig 3). 
Insert here Fig 3 
The tacrine appears inserted in the botton of the enzyme gorge, adopting a parallel n-n 
stacking interaction with Trp84 and Phe330 of CAS, and blocking the accessibility of 
substract and water to the active site (formed by the “catalytic triad” Ser200, His440 and 
Glu327);23 The benzothiazole moiety occupies the PAS having a n-n interaction with 
Trp279 and Tyr70. The structure found for these hybrid-enzyme complex models is quite 
similar to the reported crystal structure of TcAChE complexed with a tacrine-quinoline 
inhibitor (N-4'-quinolyl-N'-9"-(1",2",3",4"-tetrahydroacridinyl)-1,8-diaminooctane; PDB 
entry 1ODC),24 as shown for 10g (Fig. 3A). These simulations also indicated the capacity 
of the linker amide group to establish H-bond interactions between its NH and the phenolic 
group of Tyr121. Interestingly, in opposition to the observed previously for the 
corresponding bihybrids (TAC-SAC and TAC-SPRC),19 all the trihybrids could 
accommodate the allyl and propargyl groups outwards the lipophylic part of PAS, which is 
left free for the stronger interaction with the BTA moiety. Furthermore, these allyl and 
propargyl groups do not seem to result in considerable differences on the ligand-enzyme 
interaction (see Fig.3B for 10c and 10g). These simulations also illustrate that compounds 
with longer chains (n = 5), as 10b, have the BTA moiety slightly shifted outwards the PAS 
aromatic residues, which may result in somehow lower n-n interaction with this site than 
the shorter compounds (n = 3), as 10a (see Fig. 3C). Lastly, although 6-choro-tacrine is 
known for its higher activity, as compared with the corresponding tacrine derivatives, this 
was not clearly evidenced from the docking results, namely superimposition of 10c and 
10a (see Fig. 3D). Notably, this chloro atom (green coloured) appears to be well 
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accommodated in close distance of Hist440, which is thought to be the rationale for that 
enhancement on inhibitory activity, namely due to an H-bond interaction between its 
carbonyl oxygen and the tacrine pyridinium group.25 
Overall, the modeling studies give some support to the expected ability of the trihybrids 
to interact with both the CAS and PAS of AChE, thus explaining some of the stronger 
calculated inhibitory activities, as compared with the corresponding bihybrids. However, 
since the binding modes found for these compounds were so similar to each other, their 
relative potency as inhibitors would be difficult to predict with confidence. 
2.2 Chemistry 
The designed tacrine-S-allylcysteine-benzothiazole (TAC-SAC-BTA) and tacrine-S-
propargylcysteine-benzothiazole (TAC-SPRC-BTA) hybrids were synthesized according 
to a convergent synthetic approach shown in Scheme 1. The 9-chloro-1,2,3,4-
tetrahydroacridine (3) was prepared from commercially available anthranilic acid as 
previously reported.26,27 Amino alkyl acids were attached to the 3a and 3b, using a 
catalytic amount of KI and phenol to obtain the intermediates 2-(1,2,3,4-
tetrahydroacridine-9-ylamino) acids 4(a-d). The synthesis of the BTA-cysteine 
intermediates 9(a,b) involved four steps: firstly, L-cysteine (5) was S-alkylated with allyl 
bromide and propargyl bromide in the presence of NH4OH to yield the 3-allylsulfanyl-2-
amino-propionic acid (6a) and 2-amino-3-prop-ynylsulfanyl-propionic acid (6b), 
respectively; their amino group was Boc-protected by reaction with di-tert-butyl 
dicarbonate (Boc) to yield compounds 7(a,b); these compounds were coupled with a BTA 
unit, through the condensation of the benzothiazo-2-amine (8) to their carboxylic group 
(T3P-activated), and subsequently the Boc group was released from the amine group with 
TFA to obtain the intermediates 9(a,b). Lastly the condensation of both intermediate 
compounds 4(a-d) and 9(a,b) in the presence of T3P and NMM afforded the ultimate 
novel hybrids 10(a-h). 
Insert here Scheme 1 
2.3. Biological activity 
2.3.1. AChE inhibition 
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TcAChE enzymatic inhibition by the newly synthesized compounds 10(a-h) was 
evaluated by adaptation of a method previously described.15 The IC50 values for AChE 
inhibition are depicted in Table 1 (see also data plots in Fig. S9). These series of 
compounds showed inhibitory activity in submicromolar range, even slightly better than 
the standard drug (tacrine). Among those, as we expected, the compounds with the 
chloro-substituted tacrine moiety showed higher inhibition (IC50 = 0.25-0.28 tM), with 
no considerable difference between the propargyl/allyl cysteine substituents. Overall, the 
compound with chlorotacrine and S-propargylcysteine groups (10g) showed highest 
AChE inhibition with IC50 value of 0.25 tM, while the compound with allyl substitution 
10d exhibited inhibition with IC50 value of 0.28 tM. Generally, the size of the linker 
tested (n = 3, 5) seems to have a small effect on the inhibitory capacity of the 
compounds. Overall, comparison of the AChE inhibitory activity obtained for this series 
of trihybrids (TAC-SAC/SPRC-BTA) with that obtained previously for the 
corresponding bihybrid analogues (TAC-SAC/SPRC, see Table S1 in Supplementary 
Data),19 showed that the inclusion of the third moiety (BTA) resulted in a considerable 
enhancement (up to one order of magnitude, with IC50 in sub-µM range), attributable to 
its stronger dual-binding mode with both the CAS and PAS of AChE, especifically due 
to the strong BTA-PAS it-it interaction. 
2.3.2. Inhibition of self-mediated and Cu(II)-induced Aβ42 aggregation 
To test the anti-amyloidogenic activity of these novel trihybrid compounds, our 
experimental approach relied on in vitro assays with thioflavine T (ThT) to monitor and 
quantify the aggregation of A342 synthetic peptide into fibrils. ThT is a histochemical dye 
that is known to bind to the peptide 3-sheet conformation, which is the predominant 
secondary structure of amyloid-beta fibrils. The presence of fibrils can be monitored by 
the fluorescence emission of ThT, with the absorption peak at 446 nm and the emission 
peak at 485 nm.28,29,30 
The inhibition studies were carried out upon incubating A342 in the presence and absence of 
the ligands. The results, summarized in Table 1, showed that all the compounds induced a 
decrease of the ThT fluorescence associated with the A3 fibril binding, thus suggesting an 
inhibition of the A342 self-aggregation process. In particular, all of them 
8 
exhibited very good-to-moderate aggregation inhibitoiry capacity. Compounds 10b and 
10e showed very good inhibitory capacity (78.2% and 77.2%, respectively), while other 
sets of compounds (10a, 10c, 10f) and (10d, 10g, 10h) exhibited, respectively, good and 
moderate activities. Comparison between the anti-Af3 aggregation capacities found for 
these trihybrids (TAC-SAC-BTA and TAC-SPRC-BTA) and the previously reported 
values for corresponding bihybrids (TAC-SAC and TAC-SPRC, see Table S1)19 or tacrine 
itself, showed a general increase of up to 5-fold the percentage of inhibition for the same 
experimental conditions, which is clearly attributed to the further inclusion of the BTA 
moiety in these hybrids. Among the set of compounds studied herein, the chloro 
substitution resulted in the decrease of the interaction with Af3, with apparent slightly 
stronger effect for compounds with longer chain size. In general, the allylic derivatives led 
to a somewhat better inhibition than the corresponding propargylic ones, which may be 
due to higher rigidity and increased lipophilicity (some water solubility limitations). 
A survey on the effect of compounds on the inhibition of copper-induced Af3 aggregation 
was carried out for 10c and 10g. It was observed a higher inhibitory activity for the 
incubation of Af342 in the co-presence of copper (56.6, 37.6%) than that in its absence 
(31.6, 24.1%), thus suggesting that the ligands may modulate the metal-induced 
aggregation of Af342, similarly to previously reported for the analogues tacrine-SAC and 
TAC-SPRC.20 This can be rationalized by the metal-chelating properties of compounds 
which may compete with the amyloid peptide for the copper and decrease their 
aggregation ability, thus resulting in higher inhibition percentage. However, the 
enhancement of Af342 inhibitory activity due to the co-presence of copper observed for the 
trihybrids is lower than that previously observed for dihybrids (ca 3.8 fold, see Table 
S1),20 which may be attributed to the substitution of one N-amine by N-amide donor 
groups. 
Insert here Table1 
2.3.3. Antioxidant activity 
The newly invented trihybrid compounds of TAC-SAC-BTA and TAC-SPRC-BTA were 
screened for their antioxidant activities, based on their interaction with the 2,2-diphenyl-
1-picrylhydrazyl (DPPH) free radical.31 Analysis of the results evidenced low anti- 
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oxidant activity (EC50 > 1000 µM, see Fig. S10), similarly to tacrine and lower than the 
values previously found for the bihybrid analogues (TAC-SAC and TAC-SPRC, see 
Table S1),19 and so the particular values are not included herein (see representative plot in 
Fig. S9). These series of trihybrid compounds presented antioxidant capacity similar to 
tacrine, which is in contrast with the expectation due to the inclusion of the natural-based 
SAC and SPRC neuroprotectors.32 The recognized in vitro neuroprotective activity 
provided by these groups may be associated with an increased anti-oxidant activity inside 
the cells due to some enzymatic deprotection of the sulfhydryl group.33 
2.3.4. Inhibition of MAO 
Four of the new compounds 10(a,c,g,h) were investigated for their inhibitory activity 
against MAOs using a coupled fluorescent method.34 Compounds neither quenched the 
fluorescence of resorufin nor compromised the activity of the coupling enzyme, 
horseradish peroxidase. The IC50 values are given in Table 1. All compounds were poor 
inhibitors of MAO B (IC50 >50 µM), but were slightly more effective against MAO A that 
has a wider active site to accommodate bulky molecules. 
Without preincubation, the inhibition of MAO A was less, giving IC50 values as follows: 
10a, 48.4 µM; 10c, 25.9 µM; 10g, 42.1 µM; 10h, 87.5 µM. Thus, preincubation decreased 
the IC50 only slightly (< 3-fold) in contrast to the standard MAO A inhibitor, clorgyline, 
where the IC50 decreases 100-fold with 30 min preincubation.
35 The very small difference 
in IC50 after 30 min preincubation was the same for both the allyl and propargyl 
compounds suggesting that the new propargyl derivatives do not inactivate MAO to any 
great extent. The high IC50 values obtained when inhibitor and substrate are added at the 
same time indicate low affinity binding, so it is likely that the propargyl group is not close 
enough to the N5 of the FAD in the active site of MAO to undergo enzyme-catalyzed 
activation. 
2.3.5. Cell viability and neuroprotection 
To evaluate the potential therapeutic effect of TAC-SAC-BTA and TAC-SPRC-BTA 
compounds 10(a–h), SH-SY5Y cells were treated with A1342 peptide or H2O2 in the 
presence or absence of the tacrine hybrids. A13 peptides that accumulate in AD relevant 
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neurons are widely used to induce cell toxicity and model AD. Indeed, A13 oligomers 
induced a decrease in cell viability (Fig.4A). Despite our previous results showed that 
similar tacrine hybrids prevented from A13-induced cell toxicity.19 the addition of a new 
benzothiazol to potentiate the interaction with A13 eliminated any potential protective 
role. We may emphasize that an increased interaction between A13 peptides and our new 
tacrine hybrids 10(c,e,h) prevented A13 aggregation but still allowed soluble oligomers to 
interact with organelles, such as mitochondria and elicit its toxic effect. Nevertheless, 
compound 10d showed the lowest inhibition of Aβ aggregation (14%) very similar to our 
data obtained with previous compounds that were able to prevent A13-induced cellular 
toxicity.19 Regarding compound 10f, its highest molecular weight and lipophilicity (see 
below and Table 1S), as well as concomitant limited solubilization, may have also 
contributed for the decreasing in its cellular internalization and the lowest recovering 
effect of the amyloid stressor.. 
Additionally, it is generally accepted that AD-related neurodegenerative processes 
involve oxidative stress that may be induced by H2O2. 
Indeed, 
H2O2 (100 µM, 24 h) induced 
a decrease in cell viability in SHSY-5Y cells (see Fig. 4B). Among the tacrine hybrids 
tested 10 (b,g,h) were the most effective in preventing H2O2-mediated toxicity. These 
results are similar to those previously obtained with other tacrine hybrid compounds.19 
Insert here Fig 4 
2.3.6. Pharmacokinetic properties 
In an effort to establish the drug-likeness of the novel compounds and their potential to 
penetrate important membranes such as the blood–brain barrier (BBB), some indicators of 
their pharmacokinetic profiles were predicted using QikProp program, v. 2.5.36 
Parameters such as the calculated octanol–water partition coefficient (clogP), the ability 
to cross the BBB (log BB), the capacity to be absorbed through the intestinal tract to the 
blood (Caco-2 cell permeability), and the verification of Lipinski’s rule of five, may give 
an idea of their drug-likeness for being orally active as anti-AD agents. 
All the compounds presented clogP values greater than five (Table 1S), thus with higher 
lipophilic character than recommended by Lipinski’s rule.37 The compounds also have 
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molecular weights higher than 500, which accounts for two violations of this rule. The 
high lipophilic character and the low BBB permeability (log BB) indicate that the 
compounds are not eligible as drug candidates for oral administration. However, they 
exhibited very good results in Caco-2 permeability, ranging from ca. 600 to 1400 nm/s 
(higher than 500 nm/s is considered good)36 with compounds 10e and 10g having lower 
cell permeabilities (according to the standard value). The other compounds presented 
greater values, indicating that the absorption through the intestinal tract to the blood is 
possible. 
3. Conclusion 
The conjugation of several functional moieties in one molecular entity has recently 
emerged as an important drug development strategy to combat the complex 
multifactorial Alzheimer`s disease (AD). Following this strategy in this work, a series of 
eight novel trihybrids has been designed, prepared and bioassayed aimed at gathering 
information about potential anti-AD drug candidates. They incorporate three main 
moieties, tacrine (TAC), S-allyl- or S-propargyl-cysteine (SAC/SPRC) and 
benzothiazole (BTA), for inhibition/modulation of three main important AD targets: 
acetylcholinesterase inhibition, anti-oxidant activity and inhibition of amyloid 3 (A3) 
aggregation, with additional possible inhibition of the MAO enzyme. Analysis of the 
biological properties shown for these trihybrids was made in comparison with those 
recently reported for identical chemical library of bihybrids, lacking the BTA moiety. As 
hypothesized, the inclusion of the third moiety resulted in a considerable enhancement of 
the AChE inhibitory activity (up to one order of magnitude, with IC50 in sub-µM range, 
below that of the tacrine drug), attributed to its stronger dual-binding mode with both the 
CAS and PAS of AChE, specifically due to the strong BTA-PAS it-it interaction. Also, 
insertion of the BTA moiety on the trihybrids led to an enhancement of up to ca 5-fold 
the percentage of self-A3 aggregation inhibition, attributed to the well-known affinity of 
BTA derivatives for A3. Nevertheless, antioxidant activity of the trihybrids is lower than 
the bi-hybrids and similar to that of TAC. In addition, a preliminary study with some of 
these new trihybrids revealed only weak capacity for MAO inhibition, another known 
drug target for AD. 
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Overall, a comparative analysis of some relevant anti-AD properties of the present 
trihybrids and those of the previous bihybrid analogues shows that conjugation of these 
three structural scaffolds in a molecular unit can provide a basis for the development of 
potential multifunctional drug candidates for Alzheimer´s disease. 
4. Experimental part 
4.1. Chemistry 
General methods and materials 
Analytical grade reagents were purchased from Sigma-Aldrich, Fluka and Acros and 
were used as supplied. Solvents were dried according to standard methods38. The 
chemical reactions were monitored by TLC using alumina plates coated with silica gel 
60 F254 (Merck). Column chromatography separations were performed on silica gel 
Merck 230-400 mesh (Geduran Si 60). The melting points (m.p.) were measured with a 
Leica Galen III hot stage apparatus and are uncorrected. The 1H and 13C NMR spectra 
were recorded on Bruker AVANCE III spectrometers at 300 and 400 MHz, 
respectively. Chemical shifts (δ) are reported in ppm from the standard internal 
reference tetramethylsilane (TMS). The following abbreviations are used: s = singlet, d 
= doublet, t = triplet, m = multiplet. Mass spectra (ESI-MS) were performed on a 500 
MS LC Ion Trap (Varian Inc., Palo Alto, CA, USA) mass spectrometer equipped with 
an ESI ion source, operated in the positive ion mode. For the target compounds, the 
elemental analyses were performed on a Fisons EA1108 CHNS/O instrument and were 
within the limit of ± 0.4%. The electronic spectra were recorded with a Perkin Elmer 
Lambda 35 spectrophotometer, using thermostatic 1 cm path length cells. 
4.1.1. General procedure for the preparation of 2-(1,2,3,4-tetrahydroacridine-9-
ylamino) acid 4(a-d) 
To a mixture of 3 (1 eq) and different aliphatic acids (3-aminopropanoic, 4-
aminobuytric and 6-amino hexanoic acid (2 eq) was added to phenol and catalytic amount 
of KI. The mixture is heated at 180 oC for 4 h and then cooled to room temperature. The 
mixture is dissolved in 5% NaOH, washed with diethyl ether (3-4 times). The collected 
aqueous layer was adjusted to pH 8 with HCl, and then washed with diethyl ether (3-4 
times). The aqueous layer was acidified with HCl up to pH 2 and then 
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extracted with dichloromethane. The organic layer was dried over anhydrous Na2SO4 
and concentrated under reduced pressure to give the crude product. Purification was 
performed by column chromatography, eluent: CH2Cl2/MeOH (6/1) v/v, plus 10 mL 
25% ammonia aqueous, for 1L total solution. 
4.1.2.1. 4-(1,2,3,4-tetrahydroacridin-9-ylamino)butanoic acid (4a) 
9-Chloro-1,2,3,4-tetrahydroacridine (3a) and 4-aminobuytric acid afforded the 
pure title product as a light yellow colour solid; yield 62%; m.p. 157-160 oC; 1H NMR 
(MeOD) 5: 8.45 (d, J = 8.6 Hz, 1H, H-8), 7.85-7.73 (m, 2H,H-5 & H-6), 7.59-7.53 (m, 
1H, H-7), 4.00 (t, J = 7.0 Hz, 2H, H-1'), 3.00 (brs, 2H, H-4), 2.69 (brs, 2H, H-1), 2.50 
(t, J = 6.7 Hz, 2H, H-3'), 2.16-2.07 (m, 2H, H-2'), 1.96-1.93 (m, 4H, H-2 & H-3); MS-
ESI (m/z): 285 (M+1)+, 286 (M+2)+. 
4.1.2.2. 6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexanoic acid (4b) 
9-Chloro-1,2,3,4-tetrahydroacridine (3a) and 6-aminohexanoic acid afforded 
the pure title product as a light yellow colour solid; yield 67%; m.p. 181-183 oC; 1H 
NMR (300 MHz, MeOD) 5 8.19 (d, J = 8.5 Hz, 1H, H-8), 8.04 (d, J = 8.4 Hz, 1H, H-
5), 7.687.62 (m, 1H, H-6), 7.44-7.39 (m, 1H, H-7), 3.85 (t, J = 7.0 Hz, 2H, H-1'), 3.00 
(brs, 2H, H-4), 2.59 (brs, 2H, H-1), 2.24 (t, J = 7.0 Hz, 2H, H-5'), 1.85-1.79 (m, 6H, 
H-2, H-3, & H-2'), 1.61-1.59 (m, 2H, H-4'), 1.42-1.39 (m, 2H, H-3'); MS-ESI (m/z): 
313 (M+1)+ )+, 314 (M+2)+. 
4.1.2.3. 4-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)butanoic acid (4c) 
6,9-Chloro-1,2,3,4-tetrahydroacridine (3b) and 4-aminobuytric acid afforded the 
pure title product as a light yellow colour solid; yield 59%; m.p. 230-232 oC; 1H NMR 
(MeOD) 5: 8.45 (d, J = 8.7 Hz, 1H, H-8), 7.76 (d, J = 1.9 Hz, 1H, H-5), 7.52 (dd, J = 7.2 
&1.9 Hz, 1H, H-7), 4.00 (t, J = 6.9 Hz, 2H, H-1'), 3.00 (brs, 2H, H-4), 2.71 (brs, 2H, H1), 
2.50 (t, J = 8.1 Hz, 2H, H-3'), 2.20-2.13 (m, 2H, H-2'), 1.99-1.96 (m, 4H, H-2 & H-3); MS-
ESI (m/z): 318 (M)+, 319 (M+1)+. 
4.1.2.4. 6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexanoic acid (4d) 6,9-Chloro-
1,2,3,4-tetrahydroacridine (3b) and 6-aminohexanoic acid afforded the pure title 
product as a light yellow colour solid; yield 69%; m.p. 155-157 oC; 1H NMR 
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(300 MHz, MeOD) 5 8.39 (d, J = 8.9 Hz, H-8), 7.82 (d, J = 2.1 Hz, 1H, H-5), 7.55 (dd, 
1H, J = 7.0 & 2.1 Hz, H-7), 3.98 (t, J = 7.2 Hz, 2H, H-1′), 3.00 (br, 2H, H-4), 2.72 (br, 
2H, H-3), 2.35 (t, J = 7.2 Hz, 2H, H-5′), 2.00-1.98 (m, 4H, H-2 & H-3); 1.94-1.86 (m, 2H, 
H-2′), 1.73-1.65 (m, 2H, H-4′), 1.55-1.49 (m, 2H, H-3′); MS-ESI (m/z): 346 (M+), 347 
(M+1)+. 
4.1.4. Procedure for the preparation of 3-allylsulfanyl-2-amino-propionic acid 
(6a) and 2-amino-3-prop-ynylsulfanyl-propionic acid (6b) 
L-cysteine (1 eq) were dissolved in NH4OH solution (2M, 45 mL), and the 
reaction mixture was stirred at 0 oC around 30 min. Afterwards, allyl bromide/propargyl 
bromide (1.5 eq) was dropwise added and reaction mixture was stirred for another 3 h, 
concentrated in vaccuo and filtered; the filtrate was washed with ethanol and 
recrystallized from water-ethanol affording the pure product as white shiny particles. 
4.1.3.1. (R)-3-allylsulfanyl-2-amino-propionic acid (6a) 
L-cysteine (5) and allyl bromide afforded the pure title product as a white powder; 
yield 75%; m.p. 220-221 oC; 1H NMR (300 MHz, D2O) 5: 5.96-5.79 (m, 1H, HC=C), 
5.29-5.19 (m, 2H, CH2=CH), 3.94-3.82 (m, 1H, CHNH2), 3.21 (d, J = 7.2 Hz, 2H, CH2-
allyl), 3.00-2.94 (m, 2H, CH2CHN); MS-ESI (m/z): 160(M-1)+, 162(M+1)+. 
4.1.3.2. (R)-2-amino-3-prop-ynylsulfanyl-propionic acid (6b) 
L-cysteine (5) and propargyl bromide afforded the pure title product as a white 
shiny solids; yield 72%; m.p. 294-296 oC; 1H NMR (300 MHz, D2O) 5: 3.83-3.90 (m, 1H, 
CHNH2), 3.32-3.30 (m, 2H, CH2-propargyl), 3.24-3.01 (m, 2H, CH2CHN), 2.61 (t, J = 2.5 
Hz,1H, HCC); MS-ESI (m/z): 160 (M+1)+. 
4.1.4. Procedure for the preparation of (S)-3-(allylthio)-2-(tert-
butoxycarbonylamino)propionic acid (7a) and (S)-2-(tert-butoxycarbonylamino)-3-
(prop-2-ynylthio)propanoic acid (7b) 
Compound 6(a, b) (1 eq) and Boc anhydride (1 eq) were both dissolved and stirred 
in THF (25 mL), saturated with sodium bicarbonate solution (60 mL) and left stirring for 
5 h at room temperature. The reaction mixture was diluted with H2O (15 mL) and EtOAc 
(15 mL), the pH was adjusted to about 2-2.5, and then separate the organic 
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extracts were washed with brine and dried over Na2SO4. The solvent was removed under 
vacuum and the crude material was purified by silica gel chromatography to give 7(a,b). 
4.1.4.1. (S)-3-(allylthio)-2-(tert-butoxycarbonylamino)propanoic acid (7a) 
3-Allylsulfanyl-2-amino-propionic acid (6a) was treated with Boc anhydride to 
afford the pure title product as semi solid; yield 90%; 1H NMR (300 MHz, DMSO-d6) 5: 
7.1 (d, J = 8.3 Hz, 1H, HNCH), 5.79-5.69 (m, 1H, HC=C), 5.14-5.06 (m, 2H, CH2=HC), 
4.06-4.01(m, 1H, CHNH), 3.15 (d, J = 7.1 Hz, 2H, CH2-allyl), 2.82-2.61 (m, 2H, 
CH2CHN), 1.38 (s. 9H, tBuH); MS-ESI (m/z): 261 (M+). 
4.1.4.2. (S)-2-(tert-butoxycarbonylamino)-3-(prop-2-ynylthio)propanoic acid (7b) 
2-Amino-3-prop-ynylsulfanyl-propionic acid (6b) and Boc anhydride afforded the 
pure title product as semi solid; yield 83%; 1H NMR (300 MHz, DMSO) 5: 7.15 (d, J = 
8.4 Hz, 1H, HNCH), 4.15-4.08 (1H, m, HCNH), 3.41-3.39 (m, 2H, CH2-propargyl), 3.08-
3.81 (m, 2H, CH2CHN), 2.67 (t, J = 2.5 Hz,1H, HCC), 1.41 (s. 9H, tBuH); MS-ESI (m/z): 
259 (M+). 
4.1.5. Procedure for the preparation of tert-butyl 3-(allylthio)-1-(benzo[d]thiazol-2-
ylamino)-1-oxopropan-2-yl-carbamate (8a) and tert-butyl 1-(benzo[d]thiazol-2-
ylamino)-1-oxo-3-(prop-2-ynylthio)propan-2-yl-carbamate (8b) 
T3P (1.5 eq) was added dropwise to a stirred suspension of 2-amino benzothiazole 
(1 eq) (8), N-Boc protected SAC/SPRC (1 eq) 7(a,b) and NMM (2.5 eq) in DCM under 
nitrogen and the mixture was stirred at room temperature for 3 h; after completing the 
reaction, it was diluted with water and extracted in ethyl acetate (3×20 mL). The 
combined extracts were washed with HCl (0.1 N, 3×50 mL) and NaOH (1 N, 3×50 mL) 
and then with water and brine. The combined organic phases were dried over Na2SO4 and 
solvent was removed to afford the substitled compounds 8(a,b). 
4.1.5.1. Tert-butyl-3-(allylthio)-1-(benzo[d]thiazol-2-ylamino)-1-oxopropan-2-yl- 
carbamate (8a) 
2-Aminobenzothiazole (8) and N-Boc protected SAC (7a) afforded the pure title 
product as an colorless solid with 78% yield; m.p. 83-85 oC; 1H NMR (300 MHz, CDCl3) 5: 
7.82-7.83 (m, 2H, H-4 & H-7), 7.43 (t, J = 8.0 Hz, 1H, H-5 or H-6), 7.31 (t, J = 8.0 Hz, 1H, 
H-6 or H-5), 5.73-5.65 (m, 1H, HC=C), 5.11-5.07 (m, 2H, H2C=CH), 4.66-4.55 (m, 
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1H, HCNH), 3.08 (d, J = 7.1 Hz, 2H, CH2-allyl), 2.98-2.95 (m, 2H, CH2CHN), 1.46 (s. 
9H, tBuH); MS-ESI (m/z): 393 (M+). 
4.1.5.2. Tert-butyl-1-(benzo[d]thiazol-2-ylamino)-1-oxo-3-(prop-2-ynylthio)propan-
2-yl-carbamate (8b) 
2-Aminobenzothiazole (8) and N-Boc protected SPRC (7b) afforded the pure title 
product as an colourless solid; yield 83%; m.p.133-135 oC; 1H NMR (300 MHz, CDCl3) 
5: 7.82-7.85 (m, 2H, H-4 & H-7), 7.45 (t, J = 8.0 Hz, 1H, H-5 or H-6), 7.31 (t, J = 8.0 Hz, 
1H, H-6 or H-5), 4.82-4.80 (1H, m, HCNH), 3.26-3.22 (m, 4H, CH2-propargyl, & 
CH2CHN), 2.26 (s, 1H, HCC), 1.41 (s, 9H, tBuH); MS-ESI (m/z): 391 (M+). 
4.1.6. Procedure for the preparation of 3-(allylthio)-2-amino-N-(benzo[d]thiazol-2- 
yl)propanamide (9a) and 2-amino-N-(benzo[d]thiazol-2-yl)-3-(prop-2-  
ynylthio)propanamide (9b) 
Compounds 8(a,b) and trifluoroacetic acid (TFA, 1 mL) were dissolved DCM (2 
mL) and stirred at room temperature for 2 h. After completing the reaction, the solvent 
was evaporated and afforded the crude product and washed with diluted ammonia 
solution (10%). Purification was performed by column chromatography, eluent 
CH2Cl2/MeOH (6/1), affording pure compounds 9(a,b). 
4.1.6.1. 3-(allylthio)-2-amino-N-(benzo[d]thiazol-2-yl)propanamide (9a) 
Tert-butyl-3-(allylthio)-1-(benzo[d]thiazol-2-ylamino)-1-oxopropan-2-yl-
carbamate (8a) and TFA afforded the pure title product as a colourless solid; yield 86%; 
m.p.105-107 oC; 1H NMR (CDCl3) 5: 7.78-7.82 (m, 2H, H-4 & H-7), 7.44 (t, J = 8.0 Hz, 
1H, H-5 or H-6), 7.29 (t, J = 8.0 Hz, 1H, H-6 or H-5), 5.71-5.22 (m, 1H, HC=C), 5.135.20 
(m, 2H, H2C=CH), 3.79 (brs, 1H, HCNH), 3.08-3.15 (m, 3H, H2C-allyl & H2CCHN), 
3.09-2.80 (m, 1H, H2CCHN); MS-ESI (m/z): 293 (M+). 
4.1.6.2. 2-amino-N-(benzo[d]thiazol-2-yl)-3-(prop-2-ynylthio)propanamide (9b) 
Tert-butyl-1-(benzo[d]thiazol-2-ylamino)-1-oxo-3-(prop-2-ynylthio)propan-2-yl-
carbamate (8b) and TFA afforded the pure title product as a colourless solid; yield 89%; 
m.p.112-114 oC; 1H NMR (DMSO) 5: 7.98 (d, J = 7.8 Hz, 1H, H-4) 7.75 (d, J = 7.8 Hz, 
1H, H-7), 7.45 (t, J = 8.0 Hz, 1H, H-5 or H-6), 7.32 (t, 1H, J = 8.0 Hz, H-6 or H-5), 3.76 
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(t, J = 6.7 Hz, 1H, HCNH), 3.19 (s, J = 6.7 Hz, 2H, CH2-propargyl), 2.97-2.86 (m, 3H,-
CH2CHN & HCC); MS-ESI (m/z): 291 (M+). 
4.1.7. General procedure for the preparation of 10(a-h) 
T3P (1.5 eq) was added dropwise to a stirred suspension of BTA-SAC/BTA-SPRC 
(1 eq) 9(a,b), 2-(1,2,3,4-tetrahydroacridine-9-ylamino) acid (1 eq) 4(a-d) and NMM (2.5 
eq) in DCM under nitrogen and the mixture was stirred at room temperature for 3 h; after 
completing the reaction, it was diluted with water and extracted in ethyl acetate (3x20 
mL). The combined extracts were washed with HCl (0.1N, 3x50 mL) and NaOH (1N, 
3x50 mL) and then with water and brine. The combined organic phases were dried over 
Na2SO4 and solvent was removed to afford the substitled compounds 10(a-h). The final 
product was purified by column chromatography, eluent: CH2Cl2/MeOH (6/1) v/v, plus 
10 mL 25% ammonia aqueous, for 1L total solution and some of the compounds 
recrystalized by ethanol and ethyl ether. 
4.1.7.1. N-(3-(Allylthio)-1-(benzo[d]thiazol-2-ylamino)-1-oxopropan-2-yl)-4-(1,2,3,4-
tetrahydroacridin-9-ylamino)butanamide (10a) 
3-(Allylthio)-2-amino-N-(benzo[d]thiazol-2-yl)propanamide (9a) and 4-(1,2,3,4-
tetrahydroacridin-9-ylamino)butanoic acid (4a) afforded the pure title product as a light 
yellow color solid; yield 65%; m.p. 95-102 oC; 1H NMR (400 MHz, MeOD-d4) 6: 8.33-
8.34 (m, 1H, H-8), 7.75-7.78 (m, 2H, H-4''' & H-7'''), 7.60-7.64 (m, 2H, H-5 & H-6), 
7.47-7.52 (m, 1H, H-5''' or H-6'''), 7.40-7.41 (m, 1H, H-6''' or H-5'''), 7.29-7.30 (m, 1H, 
H-7), 5.70-5.80 (m, 1H, CH-allyl), 5.14 (d, 1H, J = 16.0 Hz, CH2-allyl), 5.08 (d, 1H, J = 
8.0 Hz, CH2-allyl), 4.72 (t, J = 8.0 Hz, 1H, H-2''), 3.88-3.90 (m, 2H, H-1'), 3.11-3.18 (m, 
3H, -SCH2-allyl & H-3''), 2.94-2.2.99 (m, 3H, H-4 & H-3''), 2.74 (brs, 2H, H-1), 2.55 (t, J 
= 8.0 Hz, 2H, H-3'), 2.10-2.15 (m, 2H, H-2'), 1.85 (brs, 4H, H-2 & H-3); 13C NMR 
(100.5 MHz, DMSO-d6) 6: 172.8, 171.0, 158.1, 157.3, 151.6, 148.9, 145.9, 134.6, 131.9, 
129.0, 126.6, 124.1, 123.9, 123.8, 122.2, 121.0, 120.0, 117.9, 115.7, 53.0, 47.9, 34.4, 
34.2, 33.1, 32.8, 31.9, 31.7, 26.8, 25.3, 22.9, 22.5; MS-ESI (m/z): 558 (M-1)+, 559 (M+), 
560 (M+1)+; Analysis calc. for C30H33N5O2S2.0.52 EtOH: C 62.83, H 6.06, N 12.01, S 11.00 
%; found: C 63.05, H 6.21, N 11.61 %. 
4.1.7.2. N-(3-(Allylthio)-1-(benzo[d]thiazol-2-ylamino)-1-oxopropan-2-yl)-6-
(1,2,3,4-tetrahydroacridin-9-ylamino)hexanamide (10b) 
3-(Allylthio)-2-amino-N-(benzo[d]thiazol-2-yl)propanamide (9a) and 6-(1,2,3,4-
tetrahydroacridin-9-ylamino)hexanoic acid (4b) afforded the pure title product as a light 
yellow color solid; yield 71 %; m.p. 96-100 oC ; 1H NMR (400 MHz, MeOD-d4) 6: 8.13 
(d, J = 8.0 Hz, 1H, H-8), 7.67-7.75(m, 2H, H-4''' & H-7'''), 7.59 (t, J = 8.0 Hz, 1H, H-5), 
7.39 (t, J = 8.0 Hz, 1H, H-6), 7.36-7.37 (m, 2H, H-5''' & H-6'''), 7.25 (t, J = 8.0 Hz, 1H, 
H-7), 5.50-5.78 (m, 1H, CH-allyl), 5.13 (d, 1H, J = 20.0 Hz, =CH2-allyl), 5.06 (d, 1H, J = 
8.0 Hz, =CH2-allyl), 4.75 (t, 1H, J = 8.0 Hz, H-2''), 3.61 (t, 2H, J = 8.0 Hz, H-1'), 3.15 (d, 
2H, J = 8.0 Hz, CH2-allyl), 2.93-2.96 (m, 3H, H-4 & H-3''), 2.86-2.88 (m, 1H, H-3''), 2.68 
(brs, 2H, H-1), 2.30 (t, J = 8.0 Hz, 2H, H-5'), 1.87 (brs, 4H, H-2 & H-3), 1.66-1.73 (m, 
4H, H-2' & H-4'), 1.42-1.45 (m, 2H, H-3'); 13C NMR (100.5 MHz, MeOD-d4) 6: 
174.7, 170.9, 159.1, 155.5, 153.1, 148.4, 144.1, 133.9, 131.9, 129.5, 125.8, 124.3, 123.7, 
123.6, 123.4, 120.8, 120.2, 116.6, 53.1, 51.8, 35.0, 34.2, 31.6, 31.4, 30.3, 29.3, 25.9, 24.9, 
24.3, 22.4, 21.7; MS-ESI (m/z): 588(M+), 589 (M+1)+, 590 (M+2)+; Analysis calc. for 
C32H37N5O2S2.0.20 EtOH.0.5 H2O: C 63.42, H 6.65, N 11.56%; found: C 63.01, H 6.62, 
N 11.37%. 
4.1.7.3. N-(3-(Allylthio)-1-(benzo[d]thiazol-2-ylamino)-1-oxopropan-2-yl)-4-(6- 
chloro-1,2,3,4-tetrahydroacridin-9-ylamino)butanamide (10c) 
3-(Allylthio)-2-amino-N-(benzo[d]thiazol-2-yl)propanamide (9a) and 4-(6-chloro-1,2,3,4-
tetrahydroacridin-9-ylamino)butanoic acid (4c) afforded the pure title product as a light 
yellow color solid; yield 61%; m.p. 195-198 oC; 1H NMR (400 MHz, MeOD-d4) 6: 8.15 
(d, J = 8.0 Hz, 1H, H-8), 7.80 (d, J = 8.0 Hz, 1H, H-5) 7.62-7.67 (m, 2H, H-4''' & H-7'''), 
7.40 (t, J = 8.0 Hz, 1H, H-7), 7.27-7.33 (m, 2H, H-5''' & H-6'''), 5.70-5.80 (m, 1H, CH-
allyl), 5.13 (d, 1H, J = 20.0 Hz, CH2-allyl), 5.07 (d, 1H, J = 8.0 Hz, CH2-allyl), 4.73 (t, J = 
8.0 Hz, 1H, H-2''), 3.68 (t, 2H, J = 8.0 Hz, H-1'), 3.14 (d, 2H, J = 8.0 Hz, - SCH2-allyl), 
2.91-294 (m, 1H, H-3''), 2.83-2.86 (m, 3H, H-4 & H-3''), 2.67 (brs, 2H, H- 
1), 2.47 (t, J = 8.0 Hz, 2H, H-3'), 2.05-2.06 (m, 2H, H-2'), 1.84 (brs, 4H, H-2 & H-3); 13C 
NMR (100.5 MHz, DMSO-d6) 6: 172.8, 171.0, 158.6, 158.0, 151.6, 148.9, 147.6, 134.6, 
133.5, 131.9, 126.7, 126.3, 124.2 124.1, 122.2 121.0, 117.9, 115.9, 53.0, 47.9, 34.2, 
33.2, 32.8, 31.9, 26.8, 25.3, 22.8, 22.4; MS-ESI (m/z): 594 (M+), 595 (M+1)+, 596 
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(M+2)+; Analysis calc. for C30H32N5O2S2Cl. 0.70 H2O: C 59.38, H 5.55, N 11.54 %; found : C 
59.07, H 5.55, N 11.36 %. 
4.1.7.4.N-(3-(Allylthio)-1-(benzo[d]thiazol-2-ylamino)-1-oxopropan-2-yl)-6-(6- 
chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexanamide (10d) 
3-(Allylthio)-2-amino-N-(benzo[d]thiazol-2-yl)propanamide (9a) and 6-(6-chloro-
1,2,3,4-tetrahydroacridin-9-ylamino)hexanoic acid (4d) afforded the pure title product as 
a light yellow color solid; yield 68 %; m.p. 94-98 oC; 1H NMR (400 MHz, MeOD-d4) 6: 
8.11 (d, J = 8.0 Hz, 1H, H-8), 7.76 (d, J = 8.0 Hz, 1H, H-4''') 7.69-7.71 (m, 2H, H-5 & 
H-7'''), 7.40 (t, J = 8.0 Hz, 1H, H-5''' or H-6'''), 7.32-7.35 (m, 1H, H-7), 7.27 (t, J = 8.0 
Hz, 1H, H-6''' or H-5'''), 5.72-5.79 (m, 1H, CH-allyl), 5.14 (d, 1H, J = 20.0 Hz, =CH2-
allyl), 5.08 (d, 1H, J = 12.0 Hz, =CH2-allyl), 4.75 (t, J = 8.0 Hz, 1H, H-2''), 3.59 (t, 2H, J 
= 8.0 Hz, H-1'), 3.15 (d, 1H, J = 4.0 Hz, CH2-allyl), 2.92-2.98 (m, 3H, H-4 & H-3''), 
2.80-2.83 (m, 1H, H-3''), 2.67 (brs, 2H, H-1), 2.30 (t, J = 8.0 Hz, 2H, H-3'), 1.88 (brs, 
4H, H-2 & H-3), 1.66-1.73 (m, 4H, H-2' & H-4'), 1.40-1.48 (m, 2H, H-3'); 13C NMR 
(100.5 MHz, DMSO-d6) 6: 172.9, 171.2, 159.7, 158.3, 150.9, 148.9, 148.0, 134.6, 132.9, 
131.9, 127.1, 126.5, 125.9, 123.8, 121.0, 119.0, 117.9, 116.3, 53.0, 48.3, 35.3, 34.2, 33.9, 
32.0, 30.7, 26.3, 25.4, 25.3, 23.0, 22.7; MS-ESI (m/z): 622 (M+), 623 (M+1)+, 624 
(M+2)+; Analysis calc. for C32H36N5O2S2Cl..0.79 EtOH: C 61.24, H 6.23, N 10.63 %; found: C 
61.08, H 6.38, N 10.30 %. 
4.1.7.5. N-(1-(Benzo[d]thiazol-2-ylamino)-1-oxo-3-(prop-2-ynylthio)propan-2-yl)-
4-(1,2,3,4-tetrahydroacridin-9-ylamino)butanamide (10e) 
2-Amino-N-(benzo[d]thiazol-2-yl)-3-(prop-2-ynylthio)propanamide (9b) and 4-(1,2,3,4-
tetrahydroacridin-9-ylamino)butanoic acid (4a) afforded the pure title product as a light 
yellow color solid; yield 63%; m.p. 105-110 oC; 1H NMR (400 MHz, MeOD-d4) 6: 8.17 (d, 
J = 8.0 Hz, 1H, H-8), 7.78 (d, J = 8.0 Hz, H-4''') 7.64-7.70 (m, 2H, H-5 & H-7'''), 7.56 (t, J 
= 8.0 Hz, 1H, H-6), 7.39 (t, 2H, J = 8.0 Hz, H-5''' & H-6'''), 7.27 (t, J = 8.0 Hz, 1H, H-7), 
4.82 (t, 1H, J = 8.0 Hz, H-2''), 3.69 (t, 2H, J = 8.0 Hz, H-1'), 3.35 (s, 2H, - SCH2-
propargyl), 3.21-3.26 (m, 1H, H-3''), 3.01-3.06 (m, 1H, H-3''), 2.90 (brs, 2H, H-4), 2.72 
(brs, 2H, H-1), 2.60 (s, 1H, -CH-propargyl), 2.48 (t, J = 8.0 Hz, 2H, H-3'), 2.04-2.09 (m, 
2H, H-3'), 1.86 (brs, 4H, H-2 & H-3); 13C NMR (100.5 MHz, DMSO-d6) 6: 172.8, 
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171.0, 158.2, 157.7, 151.1, 148.9, 146.6, 131.9, 128.6, 127.7, 126.6, 124.1, 123.8, 123.6, 
122.19, 121.0, 120.3, 116.1, 80.6, 74.4, 52.8, 48.0, 33.4, 32.8, 26.9, 25.4, 23.1, 22.7, 
19.1; MS-ESI (m/z): 556(M-1)+, 557(M+), 558 (M+1)+; Analysis calc. for 
C30H31N5O2S2·0.23 EtOH: C 63.00, H 5.66, N 12.32, S 11.28%; found: C 64.02, H 5.79, 
N 12.18%. 
4.1.7.6. N-(1-(Benzo[d]thiazol-2-ylamino)-1-oxo-3-(prop-2-ynylthio)propan-2-yl)-
6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexanamide (10f) 
2-Amino-N-(benzo[d]thiazol-2-yl)-3-(prop-2-ynylthio)propanamide (9b) and 6-(1,2,3,4-
tetrahydroacridin-9-ylamino)hexanoic acid (4b) afforded the pure title product as a light 
yellow color solid; yield 75%; m.p. 96-100 oC; 1H NMR (400 MHz, MeOD-d4) 6: 8.30 (d, 
J = 8.0 Hz, 1H, H-8), 7.78 (m, 2H, H-4′′′ & H-7′′′), 7.50-7.54 (m, 1H, H-5), 7.39 (t, 2H, J 
= 8.0 Hz, H-6), 7.26 (t, J = 8.0 Hz, 1H, H-5′′′ or H-6′′′), 7.15 (t, J = 8.0 Hz, 1H, H-6′′′ or 
H-5′′′), 6.75-6.80 (m, 1H, H-7), 4.82 (t, 1H, J = 8.0 Hz, H-2′′), 3.86 (t, 2H, J = 8.0 Hz, H-
1′), 3.37 (s, 2H, -SCH2-propargyl), 3.18-3.23 (m, 1H, H-3′′), 3.01-3.07 (m, 1H, H-3′′), 
2.93 (brs, 2H, H-4), 2.63-2.64 (m, 3H, H-1 & -CH-propargyl), 2.35 (t, J = 8.0 Hz, 2H, H-
5′), 1.91 (brs, 4H, H-2 & H-3), 1.79-187 (m, 2H, H-2′), 1.69-1.73 (m, 2H, H-4′), 
1.48-1.53 (m, 2H, H-3′); 13C NMR (100.5 MHz, DMSO-d6) 6: 173.0, 171.1, 158.3, 158.0, 
151.0, 148.9, 146.9, 131.9, 128.5, 128.3, 126.6, 124.0, 123.7, 123.6, 122.1, 121.0, 120.4, 
116.0, 80.6, 74.3, 52.8, 48.3, 35.3, 33.7, 32.9, 30.8, 26.3, 25.4, 25.3, 23.1, 22.8, 19.1; 
MS-ESI (m/z): 584(M-1)+, 585(M+), 586 (M+1)+; Analysis calc. for C30H31N5O2S2·0.51 
EtOH: C 64.06, H 6.13, N 11.49, S 10.52%; found: C 64.01, H 5.85, N 11.20%. 
4.1.7.7. N-(1-(Benzo[d]thiazol-2-ylamino)-1-oxo-3-(prop-2-ynylthio)propan-2-yl)-
4-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)butanamide (10g) 
2-Amino-N-(benzo[d]thiazol-2-yl)-3-(prop-2-ynylthio)propanamide (9b) and 4-(6-chloro-
1,2,3,4-tetrahydroacridin-9-ylamino)butanoic acid (4c) afforded the pure title product as a 
light yellow color solid; yield 63%; m.p.119-122 oC; 1H NMR (400 MHz, MeOD-d4) 6: 
8.19 (d, J = 8.0 Hz, 1H, H-8), 7.80 (d, J = 8.0 Hz, 1H, H-4′′′), 7.61-7.65 (m, 2H, H-5 & H-
7′′′), 7.41 (t, J = 8.0 Hz, 1H, H-5′′′ or H-6′′′), 7.35 (d, 1H, J = 8.0 Hz, H-7), 7.30 (t, J = 8.0 
Hz, 1H, H-6′′′ or H-5′′′), 4.80 (t, 1H, J = 8.0 Hz, H-2′′), 3.73 (t, 2H, J = 8.0 Hz, H-1′), 3.36 
(s, 2H, -SCH2-propargyl), 3.18-3.23 (m, 1H, H-3′′), 3.03-3.07 (m, 
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1H, H-3''), 2.84-2.86 (m, 2H, H-4), 2.67 (brs, 2H, H-1), 2.62 (s, 1H, -CH-propargyl), 2.49 
(t, J = 8.0 Hz, 2H, H-3'), 2.07-2.10 (m, 2H, H-3'), 1.85 (brs, 4H, H-2 & H-3); 13C NMR 
(100.5 MHz, MeOD-d4) 6: 174.4, 170.3, 158.1, 155.7, 153.4, 148.3, 144.1, 135.7, 131.9, 
126.0, 125.8, 124.3, 123.6, 122.3, 120.8, 120.3, 116.6, 114.2, 78.9, 71.6, 53.0, 49.3, 32.6, 
32.1, 30.9, 29.2, 25.8, 24.1, 22.1, 18.5; MS-ESI (m/z): 592 (M+), 593(M+1)+, 594 (M+2)+; 
Analysis calc. for C30H30N5O2S2Cl.0.98H2O.0.9EtOH: C 58.64, H 5.78, N 10.75%; found: 
C 58.06, H 5.34, N 11.07%. 
4.1.7.8. N-(1-(Benzo[d]thiazol-2-ylamino)-1-oxo-3-(prop-2-ynylthio)propan-2-yl)-
6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexanamide (10h) 
2-Amino-N-(benzo[d]thiazol-2-yl)-3-(prop-2-ynylthio)propanamide (9b) and 6-(6-chloro-
1,2,3,4-tetrahydroacridin-9-ylamino)hexanoic acid (4d) afforded the pure title product as 
a light yellow color solid; yield 70%; m.p. 98-106 oC; 1H NMR (400 MHz, MeOD-d4) 6: 
8.10 (d, J = 8.0 Hz, 1H, H-8), 7.75 (d, J = 8.0 Hz, 1H, H-4'''), 7.68-7.70 (m, 2H, H-5 & H-
7'''), 7.39 (t, J = 8.0 Hz, 1H, H-5''' or H-6'''), 7.33 (d, 1H, J = 8.0 Hz, H-7), 7.27 (t, J = 8.0 
Hz, 1H, H-6''' or H-5'''), 4.83 (t, 1H, J = 8.0 Hz, H-2''), 3.59 (t, 2H, J = 8.0 Hz, H-1'), 3.36 
(s, 2H, -SCH2-propargyl), 3.18-3.23 (m, 1H, H-3''), 3.03-3.06 (m, 1H, H-3''), 2.92 (brs, 
2H, H-4), 2.66 (brs, 2H, H-1), 2.62 (m, 1H, -CH-propargyl), 2.32 (t, J = 8.0 Hz, 2H, H-5'), 
1.88 (brs, 4H, H-2 & H-3), 1.67-1.73 (m, 4H, H-2' & H-4'), 1.42-1.48 (m, 2H, H-3'); 13C 
NMR (100.5 MHz, DMSO-d6) 6: 173.0, 170.9, 158.2, 158.0, 151.8, 148.8, 146.4, 133.7, 
131.9, 126.6, 126.3, 125.5, 124.1, 122.1, 121.0, 118.2, 115.5, 80.6, 74.3, 52.8, 48.1, 35.2, 
32.9, 30.6, 26.3, 25.3, 25.2, 22.8, 22.3, 19.1; MS-ESI (m/z): 620 (M+), 620 (M+1)+, 621 
(M+2)+; Analysis calc. for C32H34N5O2S2Cl.1.1 EtOH: C 61.23, H 6.10, N 10.44%; found: C 
61.57, H 6.15, N 9.87%. 
4.2. Molecular Modeling 
To perform our docking studies the X-ray crystallographic structure of Torpedo 
californica-AChE (TcAChE) complexed with an inhibitor was taken from RCSB Protein 
Data Bank (PDB entry 1ODC), in order to be used as receptor. This structure was chosen 
because of the similarity between its original inhibitor ((N-4'-quinolyl-N'-9"-(1",2",3",4"-
tetrahydroacridinyl)-1,8-diaminooctane) and our ligands: all have a tacrine moiety and an 
aromatic group linked through an alkyl chain.39 The original structure was treated using 
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Maestro v. 9.340 by removing the original ligand, solvent, and cocrystallization molecules, 
and then adding the hydrogen atoms. The ligands were built using Maestro, and then, 
using Ghemical v. 2.041 they were submitted to random conformational search (RCS) of 
1000 cycles, and 2500 optimization steps using Tripos 5.2 force field.42 The minimized 
ligands were docked into the AChE structure with GOLD software v. 5.1,43 and the zone 
of interest was defined as the residues within 10 Å from the original position of the ligand 
in the crystal structure. The ‘allow early termination’ option was deactivated, and the 
remaining default parameters of Gold were used. The ligands were subjected to 100 
genetic algorithm steps using ASP as fitness function. 
4.3. Prediction of pharmacokinetic properties 
To analyze the potential of the new compounds as new anti-AD drugs, a brief prediction 
on pharmacokinetic proprieties was performed in silico. Parameters such as the lipo-
hydrophilic character (clogP), blood–brain barrier partition coefficient (log BB), the 
ability to be absorbed through the intestinal tract (Caco-2 cell permeability) and CNS 
activity were calculated. 
The ligands were built and minimized as previously mentioned for the docking studies. 
The structures were submitted to the calculation of these relevant pharmacokinetic 
proprieties and descriptors using QikProp v. 2.5.36 These predictions are for orally 
delivered drugs and assume nonactive transport 
4.4. Antioxidant activity: 
The antioxidant activity was evaluated by the DPPH method previously described.31 To a 
2.5-mL solution of DPPH (0.002%) in methanol, four samples of each compound in 
solution were added in different volumes to obtain different concentrations in a 3.5-mL 
final volume. The samples were incubated for 30 min at room temperature. 
The absorbance was measured at 517 nm against the corresponding blank (methanol). The 
antioxidant activity was calculated by an Eq. (3).44 
 (3) 
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The tests were carried out in triplicate. The compound concentrations providing 50% of 
antioxidant activity (EC50) were obtained by plotting the antioxidant activity against the 
compound concentration. 
4.5. Acetylcholinesterase activity 
The enzymatic activity TcACHE was measured using an adaptation of the method 
previously described.15 The assay solution contained 374 tL of Hepes buffer (50 mM and 
pH8.0), a variable volume (10–50 tL) of the stock solution of each compound in 
methanol (1 mg/mL), 25 tL of AChE stock solution, and the necessary amount of 
methanol to attain 0.925 mL of the sample mixture in a 1-mL cuvette. The samples were 
left to incubate for 15 min, and then, 75 tL of acetylthiocholine iodide (AChI) solution 
(16 mM) and 476 tL of DTNB (3 mM), were added. The reaction was monitored for 5 
min at 405 nm. Assays were run with a blank containing all the components except 
AChE, which was replaced by Hepes buffer. The velocities of the reaction were 
calculated as well as the enzyme activity. A control reaction was carried out using the 
sample solvent (methanol) in the absence of any tested compound, and it was considered 
as 100% activity. The percentage inhibition of the enzyme activity due to the presence of 
increasing test compound concentration was calculated by the following Eq. (1) 
%I = 100-(vi /vo × 100) (1)  
in which vi is the initial reaction rate in the presence of inhibitor and vo is the initial rate of 
the control reaction. The inhibition curves were obtained by plotting the percentage of 
enzymatic inhibition versus inhibitor concentration, and a calibration curve was obtained 
from which the linear regression parameters were obtained. 
4.6. Inhibition of self-mediated and Cu(II)-induced A3 (1–42) aggregation 
Amyloid-3 peptide (1–42) (A342) was purchased from Aldrich as a lyophilized powder 
and stored at -20 °C. The samples were treated with 1,1,1,3,3,3-hexafluoropropan-2-ol 
(HFIP) to avoid self-aggregation and reserved. HFIP pretreated A342 samples were re-
solubilized with a CH3CN/Na2CO3 (300 tM)/NaOH (250 tM) (48.3:48.3:4.3,v/v/v) 
solvent mixture in order to have a stable stock solution. This A342 alkaline solution (500 
tM) was diluted in phosphate buffer (0.215 M, pH 8.0) to obtain a 40 tM solution. Due to 
the hydrophobic nature of the compounds under study, they were first dissolved in 
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methanol (1 mg/mL) and then further diluted in phosphate buffer to a final concentration 
of 480 tM. 
To study the A342 aggregation inhibition, a reported method, based on the fluorescence 
emission of thioflavin T (ThT), was followed.16,28,29 It is based on the assumption that 
reduction of the ThT fluorescence, due to competition of the compounds for the peptide 
interaction, imply reduced A3 aggregation. To study the effects of the compounds on 
copper-induced Aβ1-42 aggregation, solutions of Cu(II) (200 µM) in phosphate buffer (0.2 
M, pH 8.0) were prepared from a CuCl2 stock solution (0.015 M). The assay consisted on 
the incubation of A31-42 (40 µM) with or without Cu(II) (40 µM) in phosphate buffer with or 
without the ligands (80 µM). The incubation was performed at 37º C, for 24 h, and for the 
control, a sample of the peptide was incubated under identical conditions but without the 
inhibitor. After incubation, the samples were added to a 96-well plate (BD Falcon) with 
180 tL of 5 tM ThT in 50 mM glycine-NaOH (pH 8.5) buffer. Blank samples were 
prepared for each concentration in a similar way, devoid of peptide. After 5-min incubation 
with the dye, the ThT fluorescence was measured using a Spectramax Gemini EM 
(Molecular Devices) at the following wavelengths: 446 nm (excitation) and 485 nm 
(emission). The percent inhibition of aggregation due to the presence of the test compound 
was calculated by Eq. (2), in which IFi and IF0 corresponded to the fluorescence intensities, 
in the presence and the absence of the test 
I% = 100-(IFi/IF0 ×100) (2)  
compound, respectively, minus the fluorescence intensities due to the respective blanks. 
The reported values were obtained as the mean ± SEM of duplicate of two different 
experiments. 
4.7. MAOs Inhibition 
MAO activity was measured in 96-well plates (triplicate wells) by coupling the 
production of hydrogen peroxide is via horseradish peroxidase to a dye producing the 
fluorescent resorufin.35,45 Membrane-bound human MAO A and MAO B, horseradish 
peroxidase, and Ampliflu Red were obtained from Sigma-Aldrich (UK). For reversible 
inhibition, MAO was added last to the assay mixture containing (at final concentrations) 
20 tM Ampliflu Red, 1 U/mL horseradish peroxidase, 1 mM tyramine. To see whether 
there was irreversible inhibition; MAO and inhibitor were preincubated in 100 tL 
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phosphate buffer pH 7.5 at 30 °C for 30 min before adding 100 tL containing the rest of 
the assay components to start the reaction. Solubility limited the maximum concentration 
of inhibitor to 100 tM. The data were analyzed in Graphpad PRISM 4 using the sigmoidal 
equation constrained to a bottom value of zero. 
4.8. Cells and treatments 
Human Neuroblastoma SH-SY5Y cell line was purchased from ATCC-CRL-2266. 
Briefly, the cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) obtained 
from Gibco-Invitrogen (Life Technologies Ltd, UK) with 10% heat inactivated fetal calf 
serum, containing 50 U/mL penicillin, and 50 µg/mL streptomycin, under a humidified 
atmosphere of 95% air- 5% CO2 at 37 ºC. Cells were plated at 0.1 x 106 cells/mL for MTT 
cell proliferation assay. Medium was changed after 24 h and immediately before 
treatments. 
The tested compounds (10a, 10b, 10c, 10d, 10e, 10f, 10g, 10h) were dissolved in DMSO 
at a concentration of 25 mM and aliquots were stored at -20 ˚C. The compounds 10a, 10d 
and 10h were added to the medium at 2.5 µM final concentration; the compounds 10b 
10c, 10e, 10f, 10g were added to the medium at 1 µM final concentration; KC1 was added 
to the medium at 10 nM final concentration. The final concentration of DMSO in culture 
media did not exceed 0.05% (v/v) and no alterations on cells were observed. Cells were 
pre-incubated for 1 h with the compounds and then incubated with A342
 or
 H2O2 for another 
24 h. A342 was prepared as 276.9 µM stocks in sterile water and added to the medium to 1 
µM final concentration. H2O2 was freshly prepared as 5 mM stocks in water and added to 
the medium to 100 µM final concentrations. A342 was purchased from American Peptide 
(Sunnyvale, CA, USA) and H2O2 from Sigma Chemical Co (St. Louis, MO, USA). For all 
conditions tested, control experiments were performed in which the compounds tested, 
A342
 or
 H2O2 were not added. 
MTT cell proliferation assay 
Cell proliferation was determined by the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay.46 In viable cells, MTT is metabolized into a 
formazan that absorbs light at 570 nm. Following the cell treatment protocol the medium 
was aspirated and 0.5 mL MTT (0.5 mg/ml) was added to each well. The plate was then 
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incubated at 37 °C for 3 h. At the end of the incubation period the formazan precipitates 
were solubilized with 0.5 mL of acidic isopropanol (0.04 M HCl/isopropanol). The 
absorbance was measured at 570 nm. Cell reduction ability was expressed as a percentage 
of the untreated cells. 
All data result from the analysis of duplicates per experimental condition in at least three 
independent experiments and are expressed as the mean±SEM. Statistical analyses were 
performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). 
Statistical tests between multiple data sets and conditions were carried out using a one-
way analysis of variance (ANOVA) with pairwise multiple comparison procedures using 
the post hoc Bonferroni’s test to determine statistical significance, as appropriate. A p 
value <0.05 was considered statistically significant. 
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Scheme, Figs and tables 
 
Scheme 1. Reagents and conditions (i) POCl3, 180 oC, reflux, 3 h; (ii) 2 equiv H2N(CH2)nCO2H, 
phenol, KI, reflux, 4 h; (iii) allyl bromide (iii-1) or propargyl bromide (iii-2), NH4OH (2M), r.t., 3 
h; (iv) di-tert-butyl dicarbonate and Na2CO3, THF, r.t., 5 h; (v) 1.5 equiv T3P, 2.5 equiv NMM, 
CH2Cl2, rt, 3 h; (vi) TFA, CH2Cl2, rt, 2 h; (vii) 1.5 equiv T3P, 2.5 equiv NMM, CH2Cl2, r.t., 3 h; 
Table 1. In vitro activities of the TAC-SAC–BTA and TAC-SPRC-BTA hybrids towards the 
inhibition of AChE and MAO enzymes and also A342 aggregation (self- and Cu-induced). 
 
Compound 
Code 
R1 R2 n AChE  
inhibition  
IC50 (µM)a 
MAO A  
inhibition 
IC50
 (µM)d
 
MAO B  
inhibition  
IC50 (µM)
d 
A342 self- 
aggr. inhib.  
(%)b,c 
A342 Cu-induc. 
aggr. inhib. 
(%) 
10a H  3 0.365 16.2 63±8 57.8 - 
10b H  5 0.374   78.2 - 
10c Cl  3 0.280 10.8 55 31.6 56.6 
10d Cl  5 0.277   14.0 - 
10e H  3 0.348   77.2 - 
10f H  5 0.351   56.3 - 
10g Cl  3 0.248 27.7 85 24.1 37.6 
10h Cl  5 0.268 77.1 95 19.3 - 
Tacrine - - - 0.457   
19.5 
- 
Clorgyline     0.42x10-3 10.6 
  
 
a The values are mean of five independent experiments ± SD. 
b Inhibition of A342 aggregation (in %) without and with copper (40 tM). The thioflavin-T 
fluorescence method was used, and the measurements were carried out in the presence of 
inhibitor (80 tM). 
c The values are the mean of two independent measurements in duplicate (SEM < 10%). 
d The values are the mean of two independent measurements each with 21 points (SEM < 15%). 
Table 1S: Predicted pharmacokinetic valuesa 
S.No. Comp. 
Code 
R1 R2 MW clog P b log BB
c Caco-2 
permeability 
(nm/sec) 
Violations of 
Lipinski's 
rule of 5 
CNS 
activity 
1 10b H  559.75 5.859 -1.355 590 2 -- 
2 10c H  587.80 6.684 -1.550 613 2 -- 
3 10e Cl  594.19 6.187 -0.740 1263 2 - 
4 10f Cl  622.24 7.366 -1.281 890 2 -- 
5 10h H  557.73 
5.786 -1.508 445 2 
-- 
6 
10i 
H  585.78 
6.671 -1.308 999 2 -- 
7 
10k 
Cl  592.17 
6.231 -1.280 477 2 -- 
8 
10l 
Cl  620.23 
6.918 -1.020 1350 2 -- 
 
a Predicted values using program QikProp v. 2.534. b Calculated octanol/water partition 
coefficient. c Brain/blood partition coefficient. 
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Figure 1: Design stratergy for the novel trihybrids TAC-SAC-BTA and TAC-SPRC-BTA 
  
Figure 2: Synthesized compounds:.TAC-SAC-BTA (R2 = allyl) and TAC- SPRC-BTA (R2 = 
propargyl) 
  
A B 
C D 
Figure 3: Docking 
results for the TAC-
SAC- BTA and 
TAC- SPRC-BTA 
trihybrids with 
TcAChE: (A) 
superimposition of the original ligand (PDB entry 1ODC) (pink) and 10g (cyan); (B) 
superimposition of 10c (purple) and 10g (brown); (C) superimposition of 10b (pink) and 10a 
(cyan); (D) superimposition of 10c (pink) and 10a (blue). 
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Figure 4. Effect of the described compounds on Aβ42 peptide or H2O2 toxicity in SH-SY5Y cells. 
SH-SY5Y cells were treated with Aβ42 (1 µM) or H2O2 (100 µM) for 24 h, in the absence or the 
presence of the compounds. Evaluation of cell viability was performed by using MTT reduction 
test. Results are expressed as the percentage of SH-SY5Y untreated cells, with the mean ± 
S.E.M. derived from 3 different experiments. **p < 0.01, significantly different when compared 
with SH-SY5Y untreated cells; #p < 0.05; ##p < 0.01, significantly different when compared 
with H2O2 treated cells. 
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